Blueprint Current Ratio from 2010 to 2024

BPMC Stock  USD 94.86  0.07  0.07%   
Blueprint Medicines' Current Ratio is increasing over the years with slightly volatile fluctuation. Overall, Current Ratio is expected to go to 7.41 this year. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
3.76131452
Current Value
7.41
Quarterly Volatility
4.14558678
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Blueprint Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Blueprint main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.2 M, Interest Expense of 54.2 M or Selling General Administrative of 293.8 M, as well as many exotic indicators such as Price To Sales Ratio of 21.28, Dividend Yield of 0.001 or Operating Cycle of 361. Blueprint financial statements analysis is a perfect complement when working with Blueprint Medicines Valuation or Volatility modules.
  
This module can also supplement various Blueprint Medicines Technical models . Check out the analysis of Blueprint Medicines Correlation against competitors.

Latest Blueprint Medicines' Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Blueprint Medicines Corp over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Blueprint Medicines' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Blueprint Medicines' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 6.00 X10 Years Trend
Slightly volatile
   Current Ratio   
       Timeline  

Blueprint Current Ratio Regression Statistics

Arithmetic Mean5.59
Geometric Mean3.80
Coefficient Of Variation74.11
Mean Deviation3.17
Median5.71
Standard Deviation4.15
Sample Variance17.19
Range15.2065
R-Value0.36
Mean Square Error16.15
R-Squared0.13
Significance0.19
Slope0.33
Total Sum of Squares240.60

Blueprint Current Ratio History

2024 7.41
2023 3.76
2022 5.71
2021 3.7
2020 7.09
2019 4.85
2018 8.29

About Blueprint Medicines Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Blueprint Medicines income statement, its balance sheet, and the statement of cash flows. Blueprint Medicines investors use historical funamental indicators, such as Blueprint Medicines's Current Ratio, to determine how well the company is positioned to perform in the future. Although Blueprint Medicines investors may use each financial statement separately, they are all related. The changes in Blueprint Medicines's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Blueprint Medicines's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Blueprint Medicines Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Blueprint Medicines. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Ratio 3.76  7.41 
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Blueprint Medicines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Blueprint Medicines' short interest history, or implied volatility extrapolated from Blueprint Medicines options trading.

Pair Trading with Blueprint Medicines

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.

Moving together with Blueprint Stock

  0.65MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Blueprint Stock

  0.65VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.55TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:
Check out the analysis of Blueprint Medicines Correlation against competitors.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Blueprint Stock analysis

When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Global Correlations
Find global opportunities by holding instruments from different markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.37)
Revenue Per Share
4.118
Quarterly Revenue Growth
0.855
Return On Assets
(0.25)
Return On Equity
(1.57)
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.